UNH Stock Price Dips After Q2 Beat: Is It Still a Buy?

UnitedHealth Group (NYSE: UNH) reported its Q2 2026 results on July 16, exceeding Wall Street's expectations. The stock price has since declined 3.43%, leaving investors to question whether it remains a buy.

The company's medical care ratio improved significantly, reaching 86.7% and contributing to an operating income of $7.99 billion, up 55.17% year over year. UnitedHealthcare's operating margin expanded to 4.6% from 2.4%, while Optum's tacked on 160 basis points to hit 6.2%

However, the company's Medicare Advantage membership has contracted by 965,000 since year-end 2025, and Optum Health revenue fell 5% year over year due to a decline in value-based care patients.

The guidance for 2026 was raised, with adjusted EPS forecasted between $19.50 and $20. The company also doubled its share buyback authorization to at least $5 billion, indicating confidence in its cash conversion trajectory.